Skip to main content
Canada’s most-awarded newsroom for a reason
Enjoy unlimited digital access
$1.99
per week
for 24 weeks
Canada’s most-awarded newsroom for a reason
$1.99
per week
for 24 weeks
// //

Seagen Inc NASDAQ: SGEN-Q

Today's Change
Volume
Real-Time Last Update Last Sale Cboe BZX Real-Time

Today's Trading

Day Low 168.06
Day High 174.97
Open:170.60
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

More stories below advertisement

Description
Seagen Inc. is a biotechnology company. It discovers, develops and commercializes transformative cancer medicines. The company operates principally in California, Canada, Switzerland and the European Union. Seagen Inc., formerly known as Seattle Genetics Inc., is headquartered in the Seattle.

Fundamentals

Market Capitalization, $K
Shares Outstanding, K
36-Month Beta
Earnings Per Share (TTM)
Revenue Growth YoY
Profit Margin
5-Year Avg. Revenue Growth
5-Year Avg. Profit Growth
1-Year Total Return
3-Year Total Return
5-Year Total Return
Price/Earnings (TTM)
Price/Earnings (Forward)
Trailing Annual Dividend & Yield
Forward Annual Dividend & Yield
Most Recent Dividend
Ex-Div Date
Most Recent Split
Return on Common Equity
Return-on-Assets (Before Tax)
Debt-to-Equity Ratio
Price/Book

Earnings

Corporate earnings are provided from Zacks Investment Research, including Income Statements, Balance Sheets, Cash Flow Statements, and Statement of Retained Earnings.

Analyst Research

Analyst Ratings and Earnings Estimates are provided by Zacks Investment Research.

Moderate Buy

StockReports+

A premium report that provides detailed quantitative assessments of earnings, fundamentals, relative valuation, risk, price momentum and more. For subscribers only.

StockCalc

What is this stock worth in intrinsic value? View this premium StockCalc report to see this stock's valuation and how it was calculated using fundamental analysis. For subscribers only.

ValuEngine

A stock valuation and forecasting report include rating, fair value assessment, return forecasts, market ratio-based valuations and comparable analysis. Available for free with registration.

Latest Press Releases

Seagen and Astellas Complete Enrollment in EV-103 Trial Cohort K Combining PADCEV(R) (enfortumab vedotin-ejfv) With Pembrolizumab as First-Line Treatment for Advanced Urothelial Cancer
- Business Wire - Tue Oct 12, 7:00AM CDT
Business Wire - CMTX
Tue Oct 12, 7:00AM CDT
Seagen Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced that patient enrollment was completed in Cohort K of the phase 1b/2 EV-103 clinical trial (also known as KEYNOTE-869). The cohort is evaluating PADCEV(R) (enfortumab vedotin-ejfv) in combination with Merck's anti-PD-1 therapy KEYTRUDA(R) (pembrolizumab) as first-line treatment in patients with unresectable locally advanced or metastatic urothelial cancer who are unable to receive cisplatin-based chemotherapy in the first-line setting. Merck is known as MSD outside the United States and Canada.
Astellas and Seagen Complete Enrollment in EV-103 Trial Cohort K Combining PADCEV® (enfortumab vedotin-ejfv) with Pembrolizumab as First-Line Treatment for Advanced Urothelial Cancer
- PR Newswire - PRF - Tue Oct 12, 7:00AM CDT
PR Newswire - PRF - CMTX
Tue Oct 12, 7:00AM CDT
and , /PRNewswire/ -- Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and Seagen Inc. (Nasdaq:SGEN) today announced that patient enrollment was completed in Cohort K of the phase /2 EV-103 clinical trial (also known as KEYNOTE-869). The cohort is evaluating PADCEV (enfortumab vedotin-ejfv) in combination with Merck's anti-PD-1 therapy KEYTRUDA (pembrolizumab) as first-line treatment in patients with unresectable locally advanced or metastatic urothelial cancer who are unable to receive cisplatin-based chemotherapy in the first-line setting. Merck is known as MSD outside and .
Seagen to Host Conference Call and Webcast Discussion of Third Quarter 2021 Financial Results on October 28, 2021
- Business Wire - Thu Oct 7, 7:00AM CDT
Business Wire - CMTX
Thu Oct 7, 7:00AM CDT
Seagen Inc. (Nasdaq: SGEN) today announced that it will report its third quarter 2021 financial results on Thursday, October 28, 2021 after the close of U.S. financial markets. Following the announcement, Company management will host a conference call and webcast that day at 4:30 p.m. Eastern Time to discuss the results and provide a business update. Access to the event can be obtained as follows:
Price History Describes more index sector components

Price Performance

Period Period Low Period High Performance
1-Month 148.70 +16.16% increase
on 09/16/21
Period Open:152.09
Price movement based on the high, low and last over the given period.
177.75 -2.82% decrease
on 10/05/21
+20.64 (+13.57%) increase
since 09/15/21
3-Month 139.08 +24.19% increase
on 07/27/21
Period Open:143.97
Price movement based on the high, low and last over the given period.
177.75 -2.82% decrease
on 10/05/21
+28.76 (+19.98%) increase
since 07/15/21
52-Week 133.20 +29.68% increase
on 05/04/21
Period Open:204.49
Price movement based on the high, low and last over the given period.
207.17 -16.62% decrease
on 10/16/20
-31.76 (-15.53%) decrease
since 10/15/20

More stories below advertisement

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2021.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

© 2021 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies